PROSTATE CANCER
 
PARP inhibitor significantly extends rPFS vs. hormonal therapy
The PARP inhibitor olaparib (Lynparza) significantly extended radiographic progression-free survival compared with physician’s choice of hormonal therapy in men with metastatic castration-resistant prostate cancer who had defects in genes involved in DNA repair mechanisms.
Get the data
ADVERTISEMENT
 
Apalutamide efficacious in previously treated patients
Researchers say the use of apalutamide (Erleada) in patients with high-risk, nonmetastatic castration-resistant prostate cancer improves metastasis-free survival in patients who have previously undergone radical prostatectomy or external radiotherapy—regardless of the type of treatment they received.
Learn more
ADVERTISEMENT
 
Video: Dr. Frydenberg discusses MRI’s potential as a screening tool
Mark Frydenberg, MD, of Australia's Monash University, discusses whether multiparametric MRI is ready to be used as a screening modality for prostate cancer.
Watch the video

 
 
SURVEY
 
Is DRE still a relevant tool in the management of prostate cancer?
 
MORE FROM UROLOGY TIMES
 
New nonmetastatic PCa agents address unmet need
Fusion transcript shows potential for prostate cancer biomarker
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont